An interventional study of Added high-flow oxygen therapy and Standard care in Chronic Obstructive Pulmonary Disease Severe, Interstitial Lung Disease and Chronic Respiratory Failure With Hypoxia, sponsored by Skane University Hospital. Recruiting at 2 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Skane University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a registry-based, randomized, controlled clinical trial of the effect of added high-flow oxygen therapy (using the device Lumis HFT) during one year in people with long-term oxygen therapy (LTOT) for chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD).
This is a registry-based, randomized, controlled clinical trial of patients with LTOT for COPD or ILD recruited using the Swedish National Registry for Respiratory Failure (Swedevox) in collaboration with a research network within the Swedish Respiratory Society. The trial evaluates the effect of added high-flow oxygen therapy nighttime to the regular low-flow oxygen therapy compared with regular low-flow oxygen therapy alone up to one year.
The purpose of this project is to improve evidence-based treatment of people with chronic respiratory failure, currently about 2000 patients annually in Sweden, who have high risk of adverse events and mortality.
682 studies on the registry are indexed under Lung Diseases, Interstitial; 246 are open to participants now.
This study's planned enrollment of 310 is above the median of 60 across 386 interventional studies indexed under Lung Diseases, Interstitial.
Browse Lung Diseases, Interstitial studies →Skane University Hospital is the lead sponsor of 73 studies on the registry; 17 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intervention arm
Device: Added high-flow oxygen therapy
Comparison arm
Other: Standard care
Added high-flow oxygen therapy using the device Lumis HFT during nighttime and at the patient's discretion daytime, with the usual care (low-flow oxygen therapy) the rest of the time.
Standard care with low-flow oxygen therapy in accordance with clinical routine.
Time to first hospitalization or death from all causes
Time to first hospitalization or death from all causes during 1 year after randomization in people with COPD (assessed using nationwide registry data)
Time frame: 1 year
Time to first all-cause hospitalization or all-cause death
Time to first all-cause hospitalization or all-cause death in people with ILD (assessed using nationwide registry data)
Time frame: 1 year
Rate of hospitalizations or death from all causes
Rate of hospitalizations or death from all causes assessed using nationwide registry data
Time frame: 1 year
Hospitalization rate from all causes
Hospitalization rate from all causes assessed using nationwide registry data
Time frame: 1 year
Hospitalization rate from respiratory disease
Hospitalization rate from respiratory disease assessed using nationwide registry data
Time frame: 1 year
Number of hospitalized days
Number of hospitalized days from all-causes, respiratory and cardiovascular disease using nationwide registry data
Time frame: 1 year
Hospitalization rate from cardiovascular disease
Hospitalization rate from cardiovascular disease assessed using nationwide registry data
Time frame: 1 year
Number of admissions to intensive care unit (ICU)
Number of admissions to ICU assessed using nationwide registry data
Time frame: 1 year
Number of days in ICU
Number of days in ICU assessed using nationwide registry data
Time frame: 1 year
Mortality rate from all causes
The mortality rate from all causes assessed using nationwide registry data
Time frame: 1 year
Mortality rate from respiratory disease
The mortality rate from respiratory disease assessed using nationwide registry data
Time frame: 1 year
Mortality rate from cardiovascular disease
The mortality rate from cardiovascular disease assessed using nationwide registry data
Time frame: 1 year
Time to first exacerbation
Time to first exacerbation after randomisation, defined as time to first dispensed antibiotics and/or oral corticosteroids, ED-visit or hospitalization for exacerbation assessed using self-reported and registry data
Time frame: 1 year
Number of exacerbations
Number of exacerbations of all severity assessed using self-reported and registry data
Time frame: 1 year
Incidence of cardiovascular disease
Incidence of cardiovascular disease assessed using nationwide registry data
Time frame: 1 year
Need for home mechanical ventilation
Need for starting home mechanical ventilation assessed using nationwide registry data
Time frame: 1 year
Rate of withdrawal of long-term oxygen therapy
Rate of withdrawal of long-term oxygen therapy assessed using nationwide registry data
Time frame: 1 year
Adverse events
Self-reported adverse events since study start assessed using a postal questionnaire.
Time frame: 3 and 12 months
Primary care utilization
Self-reported number of primary care contacts since the start of the study assessed using a postal questionnaire.
Time frame: 1 year
Health-related quality of life
Self-reported health-related quality of life assessed using the EuroQol Five Dimensions - Five Levels (EQ5D-5L) questionnaire.
Time frame: 3 and 12 months
Health status
Self-reported health status assessed using the and the COPD Assessment Test (CAT) questionnaire.
Time frame: 3 and 12 months
Breathlessness at exertion
Self-reported exertional breathlessness assessed using the Dyspnoea Exertion Scale (DES) questionnaire.
Time frame: 3 and 12 months
Breathlessness
Self-reported breathlessness assessed using the Dyspnea-12 questionnaire.
Time frame: 3 and 12 months
Sleep quality
Self-reported sleep quality assessed using the modified Basic Nordic Sleep Questionnaire.
Time frame: 3 and 12 months
Physical activity
Self-reported level of physical activity assessed using the modified Grimby-Frändin questionnaire.
Time frame: 3 and 12 months
Change in health status
Self-reported change in perceived health status assessed using the Global Impression of Change (GIC) scale.
Time frame: 3 and 12 months
Nasal symptoms
Self-reported nasal symptoms assessed using the modified Björklund questionnaire.
Time frame: 3 and 12 months
Patient preference for continuing the treatment
Patients' self-reported patient preference for continuing the treatment assessed using postal questionnaire.
Time frame: 3 and 12 months
Plan to share: No — IPD cannot be shared due to restrictions in the current ethical approval. Pseudonymized IPD can be shared upon reasonable request and separate ethical approval.
Started Jun 2024 (actual). Primary completion is estimated for Dec 2028, 54 months after the start.
Of 114 non-industry interventional studies with no phase under Lung Diseases, Interstitial, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's planned 54 months is above that.
Counting every sponsor, half of 119 studies reached it within 27 months; a quarter within 14 and three quarters within 44.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Dec 2027 → Dec 2028 and completion Dec 2028 → Dec 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Skane University Hospital